Every Form 4 that Veru Inc. (VERU) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow VERU and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VERU filings page.
VERU INC. Chief Scientific Officer K. Gary Barnette reported a purchase of 1,800 shares of Veru common stock on 2026-08-13 at an average price of $2.6899 per share in an open-market or private transaction. Following this trade, his directly held position increased to 2,300 shares. The transaction was not marked as being conducted under a Rule 10b5-1 trading plan.
VERU INC. President and CEO Mitchell Steiner received a grant of options on 604,000 shares of common stock. The options have an exercise price of $2.25 per share and expire on May 4, 2036. One-third of the options vest on each of May 4, 2027, May 4, 2028, and May 4, 2029, reflecting a multi‑year compensation award tied to continued service.
VERU INC. Chief Admin Officer and CFO Michele Greco received a grant of options to purchase 164,000 shares of common stock at an exercise price of $2.25 per share. These are compensation-related awards, not open-market share purchases or sales.
According to the vesting schedule, options for one-third of the shares vest on each of May 4, 2027, May 4, 2028, and May 4, 2029, and the options expire on May 4, 2036. After this grant, Greco holds 164,000 options directly.
VERU INC. director Loren Mark Katzovitz received a grant of stock options covering 102,000 shares of common stock. The options have an exercise price of $2.25 per share and expire on May 4, 2036. One-third of the options vest on each of May 4, 2027, May 4, 2028, and May 4, 2029.
VERU INC. director Hyun Grace received a grant of options to buy 97,000 shares of common stock at an exercise price of $2.25 per share. These are compensation-related options, not an open-market purchase, and give her the right to buy shares in the future.
According to the vesting schedule, options for one-third of the shares vest on each of May 4, 2027, May 4, 2028, and May 4, 2029, with all unexercised options expiring on May 4, 2036. After this grant, she holds options for 97,000 shares directly.
VERU INC. director Michael L. Rankowitz received a grant of options on 100,000 shares of Veru common stock. The options have an exercise price of $2.25 per share and expire on May 4, 2036. One-third of the options vest on each of May 4, 2027, May 4, 2028, and May 4, 2029.
VERU INC. director Lucy Lu reported receiving a grant of 104,000 common stock options as compensation. The options have an exercise price of $2.25 per share and expire on May 4, 2036. One-third of the options vest on each of May 4, 2027, May 4, 2028, and May 4, 2029, and Lu holds 104,000 options following this grant.
VERU INC. disclosed that Chief Scientific Officer K. Gary Barnette received a compensation-related grant of stock options. The award covers 160,000 options to acquire Veru common shares at an exercise price of $2.25 per share, with all options held directly after the grant.
According to the vesting terms, options for one-third of the shares vest on each of May 4, 2027, May 4, 2028, and May 4, 2029, and the options expire on May 4, 2036. This filing reflects an equity incentive grant rather than an open-market purchase or sale.
VERU INC. Chief Corporate Officer Harry Fisch received a grant of stock options covering 160,000 shares of common stock. The options have an exercise price of $2.25 per share and expire on May 4, 2036.
According to the vesting schedule, one-third of the options vest on each of May 4, 2027, May 4, 2028, and May 4, 2029. Following this grant, Fisch holds 160,000 options to acquire VERU common shares directly, reflecting a compensation-related equity award rather than an open-market purchase.